checkAd

    DGAP-Adhoc  115  0 Kommentare Xlife Sciences nimmt CHF 5.0 Mio. durch Kapitalerhöhung auf - Seite 2

    Kontakt:
    Auskünfte für Medienschaffende: IRF Reputation AG, Valentin Handschin, handschin@irf-reputation.ch
    Auskünfte für Investoren: Xlife Sciences AG, Dennis Lennartz, dennis.lennartz@xlifesciences.ch


    Rechtlicher Hinweis (in Englisch)
    This press release may contain 'forward-looking statements', such as guidance, expectations, plans, intentions, or strategies regarding the future. These forward-looking statements are subject to risks and uncertainties. The reader is cautioned that actual future results may differ from those expressed in or implied by the statements, which constitute projections of possible developments. The company does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

    THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS FOR BACKGROUND PURPOSES ONLY AND DOES NOT PURPORT TO BE FULL OR COMPLETE. NO RELIANCE MAY BE PLACED BY ANY PERSON FOR ANY PURPOSE ON THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT OR ITS ACCURACY, FAIRNESS OR COMPLETENESS.

    THIS INFORMATION DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SHARES OR OTHER SECURITIES IN THE COMPANY TO ANY PERSON IN THE UNITED STATES OR IN ANY JURISDICTION TO WHOM OR IN WHICH SUCH OFFER OR SOLICITATION IS UNLAWFUL. IT IS NOT BEING ISSUED IN COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE RESTRICTED OR PROHIBITED BY LAW. THE DISTRIBUTION OF THIS ANNOUNCEMENT MAY BE RESTRICTED BY LAW IN CERTAIN JURISDICTIONS AND PERSONS INTO WHOSE POSSESSION ANY DOCUMENT OR OTHER INFORMATION REFERRED TO HEREIN COMES SHOULD INFORM THEMSELVES ABOUT AND OBSERVE SUCH RESTRICTION. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF THE SECURITIES LAWS OF ANY SUCH JURISDICTION. SECURITIES OF THE COMPANY ARE NOT BEING PUBLICLY OFFERED. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OF THE UNITED STATES,

    Seite 2 von 3


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-Adhoc Xlife Sciences nimmt CHF 5.0 Mio. durch Kapitalerhöhung auf - Seite 2 DGAP-Ad-hoc: Xlife Sciences AG / Schlagwort(e): Kapitalerhöhung Xlife Sciences nimmt CHF 5.0 Mio. durch Kapitalerhöhung auf 26.01.2022 / 07:30 CET/CEST Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014, …